Non-Hodgkin Lymphoma (NHL)

The patient had both classical Hodgkin lymphoma and diffuse large B-cell lymphoma.

Investigators are optimistic about bispecific antibodies (BsAbs) for patients with diffuse large B-cell lymphoma (DLBCL), especially the possibility of combining different BsAbs with distinct targets for stronger treatment outcomes.

Other viral infections, including Epstein-Barr virus and hepatitis C, have already been linked with primary hepatic lymphoma, the authors said.

A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

A real-world comparison of 2 chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel and tisagenlecleucel—suggests the former is associated with better efficacy but higher toxicity.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses T-cell engager therapies in the diffuse large B-cell lymphoma (DLBCL) landscape.

The authors say their 3D model improves on results using traditional 2-dimensional approaches.

Among the 10 patients in the retrospective analysis, the median overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) was 21 months.

The authors suggest the phenomenon of 2 mutationally distinct diffuse large B-cell lymphomas (DLBCLs) might be more common than currently understood.

A record 21.3 million people signed up for health insurance this year using the Affordable Care Act (ACA) marketplaces; nearly 80% of health care providers think it is important for their hospital to minimize its environmental impact; the FDA noted a potential link between CAR-T products and the development of T-cell cancer.

New methods of classifying patients could pave the way for more personalized treatment approaches, a new report states.

Although ibrutinib adds to the cost of treatment, its benefits over the long term justify the cost, investigators found.

Most patients in the cohort received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for first-line therapy; hospitalization was prevalent; and average medical and pharmacy costs were more than $140,000 per patient per year.

Salvage radiation therapy (RT) showed efficacy in local control of relapsed or refractory large B-cell lymphoma (LBCL) following CD19-targeted chimeric antigen receptor (CAR) T-cell therapy failure.

Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.

A PET-based radiomics signature was able to predict the efficacy of chimeric antigen receptor (CAR) T-cell therapy and performed better than conventional PET biomarkers in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

The review summarized existing evidence around short- and long-term treatment-related toxicities among adolescents and young adults (AYAs), as well as gaps in care guidelines for AYA survivors of lymphoma.

The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.

An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory (R/R) large B-cell lymphoma (LBCL).

Investigators said the fact that their patient was 82 years old was one reason to suspect fluid overload–associated large B-cell lymphoma (LBCL).

Recognition of the association between breast implants and lymphomas has been notable since the 1990s, although the association has been limited to breast implant–associated anaplastic large cell lymphoma and not Epstein-Barr virus (EBV).

Those with the infection who underwent treatment exhibited improved outcomes compared with patients without the infection.

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin subtype in individuals living with HIV.